Quality of original and biosimilar epoetin products

Pharmaceutical Research

Volumn 28, Issue 2, 2011, Pages 386-393

  Brinks, Vera ^a   Hawe, Andrea ^b   Basmeleh, Abdul H H ^a   Joachin Rodriguez, Liliana ^a   Haselberg, Rob ^a   Somsen, Govert W ^a   Jiskoot, Wim ^b   Schellekens, Huub ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

biosimilar; immunogenicity; protein characterization; recombinant human erythropoietin

Indexed keywords

EXCIPIENT; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAPILLARY ZONE ELECTROPHORESIS; CONTROLLED STUDY; DRUG LABELING; DRUG POTENCY; DRUG QUALITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL PRODUCTS; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, CAPILLARY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN, RECOMBINANT; MICE; PROTEIN ISOFORMS; THERAPEUTIC EQUIVALENCY;

EID: 79952488808     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0288-2     Document Type: Article

References (26)

1. Schellekens H. How similar do 'biosimilars' need to be? Nat Biotechnol. 2004;22:1357-9.
2. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm. 2004;3:43-7.
3. EMEA/CHMP/94528/2005. Guideline on similar biological medicinal products. In 2005.
4. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48:1754-62.
5. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005;18:473-80. (Pubitemid 40425360)
6. Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant. 2005;20 Suppl 3:iii33-40.
7. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res. 2003;20:1903-7.
8. Hermeling S, Jiskoot W, Crommelin DJ, Schellekens H. Reaction to the paper: interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm Res. 2006;23:641-2.
9. Schellekens H. Erythropoietic proteins and antibody-mediated pure red cell aplasia: a potential role for micelles. Nephrol Dial Transplant. 2004;19:2422. (Pubitemid 39214152)
10. Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol. 2006;3:123-30.
11. Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, Supasyndh O, Jootar S, Intarakumthornchai T, et al. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309. Nephrol Dial Transplant. 2009;24:1545-9.
12. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry. 1996;35:1681-91. (Pubitemid 26055303)
13. Bollag DM, Edelstein SJ. Protein methods. New York: Wiley-Liss; 1991.
14. Zhang J, Chakraborty U, Villalobos AP, Brown JM, Foley JP. Optimization and qualification of capillary zone electrophoresis method for glycoprotein isoform distribution of erythropoietin for quality control laboratory. J Pharm Biomed Anal. 2009;50:538-43.
15. European Pharmacopoeia 2. In 2005, pp. 1528-9.
16. Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica. 1998;83:724-32. (Pubitemid 28492155)
17. European Medicines Evaluation Agency.HX575.Scientific discussion. Available at www emea europa eu/humandocs/PDFs/EPAR/epoetinalfahexal/H-726-. (2007).
18. Llop E, Gutierrez-Gallego R, Segura J, Mallorqui J, Pascual JA. Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo). Anal Biochem. 2008;383:243-54.
19. Brooks SA. Strategies for analysis of the glycosylation of proteins: current status and future perspectives. Mol Biotechnol. 2009;43:76-88.
20. Toyoda T, Itai T, Arakawa T, Aoki KH, Yamaguchi H. Stabilization of human recombinant erythropoietin through interactions with the highly branched N-glycans. J Biochem. 2000;128:731-7.
21. Delorme E, Lorenzini T, Giffin J, Martin F, Jacobsen F, Boone T, et al. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry. 1992;31:9871-6.
22. Takeuchi M, Inoue N, Strickland TW, Kubota M, Wada M, Shimizu R, et al. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc Natl Acad Sci USA. 1989;86:7819-22. (Pubitemid 19265277)
23. Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol. 2004;57:1086-95. (Pubitemid 39446648)
24. Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW, Brookhart MA. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf. 2009;18:932-40.
25. Brown KR, Carter Jr W, Lombardi GE. Recombinant erythropoietin overdose. Am J Emerg Med. 1993;11:619-21. (Pubitemid 23340150)
26. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci. 2006;95:1084-96. (Pubitemid 43723167)